Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Lucid Diagnostics Inc (LUCD)

Lucid Diagnostics Inc (LUCD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 165,220
  • Shares Outstanding, K 137,683
  • Annual Sales, $ 4,350 K
  • Annual Income, $ -45,530 K
  • EBIT $ -48 M
  • EBITDA $ -46 M
  • 60-Month Beta 1.22
  • Price/Sales 23.02
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.08
  • Number of Estimates 1
  • High Estimate -0.08
  • Low Estimate -0.08
  • Prior Year -0.21
  • Growth Rate Est. (year over year) +61.90%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.0500 +16.19%
on 01/22/26
1.6293 -25.12%
on 01/21/26
+0.0300 (+2.52%)
since 01/12/26
3-Month
0.9923 +22.95%
on 12/03/25
1.6293 -25.12%
on 01/21/26
+0.1100 (+9.91%)
since 11/12/25
52-Week
0.9495 +28.49%
on 08/01/25
1.8000 -32.22%
on 04/08/25
-0.1100 (-8.27%)
since 02/12/25

Most Recent Stories

More News
PAVmed Closes Preferred Stock and Senior Secured Note Financings, Eliminating All Previously Outstanding Convertible Securities

Series D Preferred Stock offering yielded $30 million of gross proceeds and includes warrants exercisable for up to an additional $30 million upon publication of a positive draft EsoGuard Medicare local...

LUCD : 1.2200 (+1.67%)
PAVM : 10.28 (-1.72%)
Lucid Diagnostics Awarded U.S. Department of Veterans Affairs Contract for EsoGuard®

NEW YORK , Jan. 21, 2026 /PRNewswire/ -- Lucid Diagnostics Inc.  (Nasdaq: LUCD)  ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics...

LUCD : 1.2200 (+1.67%)
PAVM : 10.28 (-1.72%)
PAVmed Announces Reverse Stock Split

NEW YORK , Dec. 30, 2025 /PRNewswire/ --  PAVmed Inc.  (NASDAQ: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical...

LUCD : 1.2200 (+1.67%)
PAVM : 10.28 (-1.72%)
Lucid Diagnostics Announces Positive Data from the Largest Reported Real-World Experience of Esophageal Precancer Detection

Report includes nearly 12,000 patients who underwent Lucid's EsoGuard ® Esophageal DNA Test on samples collected using its EsoCheck ® Esophageal Cell Collection Device

LUCD : 1.2200 (+1.67%)
PAVM : 10.28 (-1.72%)
Lucid Diagnostics Named a GenomeWeb 2025 Best Places to Work Top-Ranking Honoree

Recognized as the leading company in its size category in program honoring the top workplaces across the diagnostics and precision-medicine sectors

LUCD : 1.2200 (+1.67%)
PAVM : 10.28 (-1.72%)
PAVmed Provides Business Update and Reports Third Quarter 2025 Financial Results

Veris Health launched commercial phase of strategic partnership and relaunched development of implantable physiological monitor

LUCD : 1.2200 (+1.67%)
PAVM : 10.28 (-1.72%)
Lucid Diagnostics Provides Business Update and Reports Third Quarter 2025 Financial Results

Processed 2,841 EsoGuard ® tests and recognized 3Q25 revenue of $1.2 million, ending quarter with over $47 million in proforma cash and extending runway through 2026 and well past upcoming reimbursement...

LUCD : 1.2200 (+1.67%)
PAVM : 10.28 (-1.72%)
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 12, 2025

Conference Call and Webcast at 8:30 AM Eastern Time

LUCD : 1.2200 (+1.67%)
PAVM : 10.28 (-1.72%)
Lucid Diagnostics to Participate in the 2025 Maxim Growth Summit

NEW YORK , Oct. 15, 2025 /PRNewswire/ --  Lucid Diagnostics Inc.  (Nasdaq: LUCD)  ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and...

LUCD : 1.2200 (+1.67%)
PAVM : 10.28 (-1.72%)
Lucid Diagnostics Appoints Healthcare Industry Veteran John R. Palumbo to Board of Directors

Growth-focused healthcare executive brings 40 years of executive leadership experience across multiple industry sectors

LUCD : 1.2200 (+1.67%)
PAVM : 10.28 (-1.72%)

Business Summary

Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. Lucid Diagnostics Inc. is based in NEW YORK.

See More

Key Turning Points

3rd Resistance Point 1.2900
2nd Resistance Point 1.2600
1st Resistance Point 1.2400
Last Price 1.2200
1st Support Level 1.1900
2nd Support Level 1.1600
3rd Support Level 1.1400

See More

52-Week High 1.8000
Fibonacci 61.8% 1.4751
Fibonacci 50% 1.3748
Fibonacci 38.2% 1.2744
Last Price 1.2200
52-Week Low 0.9495

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar